OVERVIEW: The Cure Starts Now Foundation backs pediatric brain cancer research projects, giving preference to those focusing on Diffuse Intrinsic Pontine Glioma.
IP TAKE: This foundation’s research funding has been ramping up in recent years. Grantseekers should note that it uses a modified version of the NIH grant application scoring system, so applicants should brush up on their knowledge of the system before approaching Cure Starts Now.
PROFILE: The founding of the Cure Starts Now Foundation (CSN) was inspired by a little girl named Elena who passed away from brainstem glioma when she was just five years old. Since those early days, the foundation has been laser-focused on finding a cure for brainstem glioma and other forms of cancer.
The foundation awards biannual research grants to both institutions and medical professionals who focus on pediatric brain cancers. A specific funding interest for the foundation is research related to Diffuse Intrinsic Pontine Glioma (DIPG), the disease CSN originally targeted.
The foundation backs translation and clinical research projects with initial one-year, $100,000 grants. CSN's medical advisory chair occasionally approve grants for over $100,000. Members of the DIPG Collaborative—a group of 20 foundations “seeking transparency, the elimination of duplication, efficiency, and collaboration in research of DIPG”—are eligible to apply for funding of $200,000 over one year. To learn more about the types of projects and organizations receiving CSN support, visit the Grants Awarded page on its website.
CSN accepts unsolicited grant application during its single funding cycle each year. Applications must be received by June 1. Again, the medical advisory council chair can consider applications submitted after the June 1 deadline. Applicants must be MDs, DOs, PhDs, Doctors of Public Health (DrPH) or the equivalent to be eligible for a CSN research grant. Applicants must also be a member of a related nonprofit, medical or scientific organization.
- Keith Desserich, Chairman and Founder
- Gavin Baumgardner, Chairman, Medical Advisory Council